Cited 41 times in
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2014-12-19T16:25:33Z | - |
dc.date.available | 2014-12-19T16:25:33Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89502 | - |
dc.description.abstract | We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2 and vincristine 1.4 mg/m2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1–5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77–98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antibodies, Monoclonal, Murine-Derived/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Cyclophosphamide/therapeutic use* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Therapy, Combination/methods* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glucocorticoids/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma, B-Cell, Marginal Zone/drug therapy* | - |
dc.subject.MESH | Lymphoma, B-Cell, Marginal Zone/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prednisolone/therapeutic use* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Rituximab | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Vincristine/therapeutic use* | - |
dc.title | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Je-Jung Lee | - |
dc.contributor.googleauthor | Deok-Hwan Yang | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Se-Ryeon Lee | - |
dc.contributor.googleauthor | Gyeong-Won Lee | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Ho Young Kim | - |
dc.contributor.googleauthor | Sung Yong Oh | - |
dc.contributor.googleauthor | Hugh Chul Kim | - |
dc.contributor.googleauthor | Hyeon-Seok Eom | - |
dc.contributor.googleauthor | Jooseop Chung | - |
dc.contributor.googleauthor | Jinny Park | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Baek-Yeol Ryoo | - |
dc.identifier.doi | 10.1007/s00277-011-1337-6 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J00161 | - |
dc.identifier.eissn | 1432-0584 | - |
dc.identifier.pmid | 21922208 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00277-011-1337-6 | - |
dc.subject.keyword | CVP | - |
dc.subject.keyword | First-line | - |
dc.subject.keyword | Immunochemotherapy | - |
dc.subject.keyword | Marginal zone lymphoma | - |
dc.subject.keyword | Rituximab | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.citation.volume | 91 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 543 | - |
dc.citation.endPage | 551 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, Vol.91(4) : 543-551, 2012 | - |
dc.identifier.rimsid | 31812 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.